Brian Mendelsohn BSc, PhD

Brian worked at Seattle Genetics back in the early days (2000 until 2005) working on the vcMMAE and mcMMAF drug linkers for ADC technology, which resulted in the current commercial success with Adcetris, and many more compounds in clinical trials. He was the first person to ever synthesize the MMAE drug molecule. In 2005, Brian went to the University of British Columbia to finish his Ph.D. in chemistry, focusing on the synthesis of natural product toxin molecules. He then started work at Agensys in early 2011 and built a Chemistry group with capabilities to perform novel ADC-relevant drug-linker synthesis. Currently, Brian is a Director at Ajinomoto.